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ABSTRACT 
 
Uromodulin is the most abundant protein secreted in urine where it is found as high molecular 
weight polymers. It is exclusively expressed in the thick ascending limb of Henle’s loop and 
its biological function is still elusive. Mutations in uromodulin are responsible for autosomal 
dominant kidney diseases characterised by defective urine concentrating ability, 
hyperuricaemia and gout, tubulo-interstitial fibrosis, renal cysts and chronic kidney disease. 
Previous in vitro studies have pointed at retention in the endoplasmic reticulum as a common 
feature of all uromodulin mutant isoforms. We here report in vitro and in vivo evidence that 
mutant uromodulin isoforms can partially escape retention in the endoplasmic reticulum and 
reach the plasma membrane. Here mutant protein forms large extracellular aggregates that 
play a dominant negative effect on co-expressed wild-type protein. Notably, we demonstrate 
for the first time that mutant uromodulin excretion can be detected in patients carrying 
uromodulin mutations. Overall, these results open the interesting possibility that the 
proteotoxic effect of mutant uromodulin expression could be exerted both by intra- and 
extracellular gain of function mechanisms and have implications for therapeutic strategies. 
 
Keywords: uromodulin, Tamm-Horsfall protein, urinary protein secretion, aggregation 
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INTRODUCTION 
 
Uromodulin, also known as Tamm-Horsfall protein, was discovered in 1950 by Tamm and 
Horsfall (1). It is a large glycoprotein of about 105 kDa that is exclusively expressed in the 
kidney in the thick ascending limb (TAL) of Henle’s loop. Uromodulin is a 
glycosylphosphatidylinositol (GPI)-anchored protein mainly localised at the apical plasma 
membrane of epithelial tubular cells (2), from which it is released into the tubular lumen 
through a proteolytic cleavage by a yet to be identified protease (3). In the urine, it constitutes 
the most abundant protein and it is mainly found as a high-molecular-weight polymer (Mr 1–
10 x 106) (4). 
 
Mutations in the UMOD gene encoding uromodulin have been shown to cause medullary 
cystic kidney disease type 2 (MCKD2; MIM 603860), familial juvenile hyperuricemic 
nephropathy (FJHN; MIM 162000) (5) and glomerulocystic kidney disease with 
hyperuricemia (GCKD; MIM 609886) (6, 7), collectively referred to as uromodulin-
associated kidney diseases (UAKD). UAKD are autosomal-dominant disorders characterised 
by alteration of urinary concentrating ability and by tubulo-interstitial fibrosis, 
hyperuricaemia and gout, and in few cases by renal cysts at the cortico-medullary junction 
(8). Although UAKD are heterogeneous in terms of age at onset, clinical features and 
presence of cysts, they invariably lead to chronic kidney disease (CKD) during the third to 
fifth decade of life. 
 
To date 51 mutations have been described. All but three (in-frame deletions) are missense 
changes that are clustered in the N-terminal half of the protein. In vitro studies performed in 
diverse cell lines have shown that mutant uromodulin isoforms are defective in trafficking to 
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the plasma membrane and are retained in the ER (9-12). Enrichment and aggregation of 
mutant uromodulin in the ER have been confirmed in a transgenic mouse model that we 
recently reported and in patient biopsies (10, 13). All together these results suggest ER 
retention of mutant uromodulin as a key primary event in UAKD pathogenesis. Interestingly, 
both in vitro and in vivo models show that mutant uromodulin can in part reach the plasma 
membrane carrying mature, post-ER type of glycans (9, 10, 13). 
 
In this study, we investigate the effect of mutant uromodulin escaping ER quality control. We 
show that both in in vitro and in vivo models it forms aggregates at the plasma membrane and 
in the tubule lumen. Moreover, we provide novel evidence supporting that these changes in 
the extracellular compartment might be relevant in the human disease, as we identified mutant 
uromodulin secretion in urine samples from UAKD patients. All together, our data suggest 
the possibility of an extracellular gain of function and dominant negative effect of mutant 
uromodulin isoforms. 
 
RESULTS 
 
Mutant uromodulin is trafficked to and aggregates at the plasma membrane 
We investigated if mutant uromodulin can partially escape quality control in the ER and is 
trafficked to the plasma membrane. To do so, wild-type and mutant (R212C, C256Y and 
C317Y) human uromodulin isoforms were stably expressed in MDCK cells. The C317Y 
mutation was previously reported and partially characterised in vitro (6, 14). Uromodulin 
mutations R212C and C256Y are novel and were identified after genetic screening in Italian 
UAKD families (Figure 1a, b). Similarly to previous studies on uromodulin mutants, all 
analysed mutations lead to partial ER retention of mutant protein (Figure 2a, b). Interestingly, 
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wild-type protein reaching the plasma membrane assembles into polymeric filaments as 
described for urinary protein (15) (Figure 3). Although less efficiently, all mutant isoforms 
were also trafficked to the plasma membrane and secreted in the culturing medium. Notably, 
mutant protein is unable to assemble into ordered filaments but rather forms large aggregates 
on the plasma membrane. Mutant uromodulin reaching the plasma membrane and released by 
phospholipase C (PLC) digestion, carries mature post-ER glycosylation, demonstrating that it 
escaped the ER quality control and entered the secretory pathway (Figure S1).  
 
Dominant negative effect of extracellular mutant uromodulin on the polymerisation of the 
wild-type isoform 
To verify if aggregation of mutant uromodulin isoforms on the plasma membrane could be 
detrimental for the polymerisation of the wild-type one, wild-type and mutant proteins were 
stably co-expressed in MDCK cells, mimicking the patient heterozygous state. Equal 
expression level of the two isoforms was ensured by using a bicistronic expression vector. On 
western-blot, co-expression of both isoforms did not alter the band pattern observed when 
wild-type and mutants were expressed alone, nor secretion of the wild type protein (Figure 
S2). This shows that despite ER retention of mutant protein, trafficking of the co-expressed 
wild-type one is not altered or at least not to an extent that can be detected in our experiments. 
Interestingly, immunofluorescence analysis on non-permeabilised cells shows that mutant 
protein reaching the plasma membrane co-localises with the wild-type one in shortened and 
less structured polymers, when compared to cells expressing wild-type protein only (Figure 
4a). This was confirmed both by the quantification of the average area of filament clusters 
(Figure 4b) and by differential migration on sucrose gradient (Figure 5). Indeed, 
sedimentation of wild type protein polymers into higher density fractions suggests that they 
are larger that the ones containing also mutant isoforms (16). This effect is mediated by co-
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assembly of the two isoforms as demonstrated by co-immunoprecipitation of secreted wild-
type and mutant uromodulin (Figure 6). Taken together, these results demonstrate that mutant 
uromodulin isoforms that reach the plasma membrane exert an extracellular dominant 
negative effect on wild-type protein polymerisation. 
 
Mutant uromodulin is secreted in the urine of a transgenic mouse model of UAKD and 
forms intraluminal casts 
We verified whether mutant uromodulin could indeed escape ER retention and form 
extracellular aggregates in vivo in a transgenic mouse model of UAKD (TgUmodC147W) that 
expresses HA-tagged mutant uromodulin (C147W) (13), corresponding to the patient 
mutation C148W that we already characterised in vitro (6, 9). As a first evidence of mutant 
uromodulin trafficking to the plasma membrane, we detected its presence in the urine of 12 
weeks-old TgUmodC147W mice that still have preserved renal function (unpublished data) and no 
tubular damage. At this age secretion of transgenic uromodulin is similar to the one in 
expression-matched mice transgenic for HA-tagged wild-type uromodulin (TgUmodwt) (Figure 
7a). Interestingly, urinary mutant uromodulin migrates slightly slower than the wild-type one 
on SDS-PAGE. This size difference is eliminated by PNGase F digestion, suggesting that the 
two isoforms carry different N-glycosylation. Immunofluorescence performed on mouse 
kidney sections confirms the presence of extracellular mutant uromodulin in the lumen of 
TAL tubules. Similarly to what observed in vitro, mutant protein tends to form aggregates that 
are never observed in TgUmodwt mice (Figure 7b, c). 
 
Mutant uromodulin is secreted in the urine of UAKD patients 
We assessed the relevance of our in vitro and in vivo observations by investigating whether 
secretion of mutant uromodulin could also be observed in UAKD patients. We analysed the 
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secretion of mutant uromodulin in 3 patients bearing different uromodulin mutations (R212C, 
C256Y or C317Y) (Figure 1a) and with preserved renal function (Table 1). Mass 
spectrometry analyses show that in all cases, mutant isoforms are secreted in urine (Figure 
S3-S5). Because summed peptide intensity can be used as a good proxy for absolute protein 
abundance (17), the intensity signals of peptides specifically assigned to the wild-type protein 
were compared to the ones of peptides specifically assigned to the mutant proteins, whereas 
signal intensities of common peptides of both isoforms were not considered. This method was 
used to have an estimate of the abundance of the urinary wild-type and mutant uromodulin 
isoforms in each patient. The ratio of the summed intensities of the specific peptides 
belonging to each uromodulin form is reported in Table 2. Mutant isoforms R212C, C256Y 
and C317Y secretion was estimated to represent about 1.3%, 7.6% and 35% respectively of 
the wild-type one. 
 
DISCUSSION 
 
To date 51 mutations in the UMOD gene coding for uromodulin have been described, all 
leading to UAKD. Previous in vitro studies have pointed at ER retention as a common feature 
of all investigated mutants (9-12). This was confirmed in a recently generated UAKD mouse 
model and on patient renal biopsy analysis (10, 13). All together these data led to propose that 
mutant uromodulin intracellular aggregation could play a key role in the pathogenesis of the 
disease, likely by exerting a gain-of-function effect through activation of cell stress responses. 
 
In this study through in vitro and in vivo analyses we demonstrate that part of mutant protein 
can escape the ER quality control, is trafficked to the plasma membrane and secreted. 
Interestingly, mutant protein tends to form large extracellular aggregates that interfere with 
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wild-type protein polymerisation, suggesting extracellular gain of toxic function as an 
additional consequence of uromodulin mutations. 
 
This effect was clearly evident in in vitro studies that were carried out in MDCK cells that to 
our knowledge are the only cell model able to induce proper uromodulin polymerisation into 
highly-ordered filaments. This allowed us to show that mutant isoforms are unable to 
polymerise but rather form aggregates at the plasma membrane. Moreover, when wild-type 
and mutant uromodulin were co-expressed at equal levels, thereby mimicking the patient 
condition, we observed that mutant protein co-assembles with the wild-type one and exerts a 
dominant negative effect over polymer formation and/or stability. Indeed, the presence of the 
mutant protein significantly shortens the polymers, as demonstrated by their quantification in 
immunofluorescence and their differential sedimentation on sucrose gradient. The dominant 
negative effect on protein polymerisation suggests that even if mutant protein has escaped the 
cellular quality control, it is still adopting a non-native conformation. ER quality control 
escape has already been observed for other disease-causing mutant proteins, e.g. alpha-1-
antitrypsin (18) and CFTR (19). Interestingly, CFTR folding mutant ∆F508 on escape from 
the ER quality control is altering cellular lipid trafficking (20), showing that misfolded 
proteins that gain access to the distal secretory pathway, in addition of being non functional, 
can have a detrimental effect. 
 
In the case of mutant uromodulin, this effect is not only evident in in vitro models but also in 
vivo. Indeed, immunofluorescence analyses performed on kidney sections of a mouse model 
of UAKD (TgUmodC147W mice) show intraluminal casts containing mutant uromodulin. These 
structures are an early finding in the mouse disease that can be found in virtually all TAL 
 11 
segments at time points (1 and 4 weeks of age) when renal function and nephron integrity are 
still preserved (Figure S6 and data not shown).  
 
We believe that secretion of mutant uromodulin as seen in MDCK cells and in TgUmodC147W 
mice is not merely due to overexpression. The relevance of these findings is indeed 
demonstrated by the detection of mutant uromodulin in the urine of three UAKD patients 
carrying three different mutations. Urinary mutant protein is likely derived from active 
protein secretion from the plasma membrane and not due to the presence of cell debris in the 
urine sample. Indeed, if that was the case, one would expect mutant uromodulin to be mainly 
present as the shorter ER-glycosylated isoform, which was never detected in western-blots of 
patient urine. Mutant uromodulin was not found in the urine of UAKD patients in two earlier 
studies (21, 22). This discrepancy could be ascribed to the different UMOD mutations 
analysed. However, it should be noticed that in both previous studies uromodulin secretion 
was assessed at a time point when renal function of UAKD patients was already severely 
compromised. In this condition, total uromodulin secretion was highly reduced, possibly to 
such an extent to hamper the specific detection of mutant protein. In our experience, this was 
indeed the case in affected relatives of the patients analysed in the current study that had 
reduced renal function (data not shown). This suggests that a mutation-specific effect is 
unlikely. Rather mutant uromodulin secretion (ranging from about 1 to 30 percent of the wild-
type protein level in our work) is evident in UAKD patients when renal function is still 
preserved. 
 
What could be the consequences of extracellular mutant uromodulin aggregation? It is well 
known that uromodulin constitutes the matrix for the formation of hyaline casts (23). Mutant 
uromodulin with its high propensity to aggregation could increase the number of hyaline casts 
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formed in the TAL leading to tubule obstruction, an event that could be upstream of 
inflammation and interstitial fibrosis. On a more speculative ground, we hypothesise that 
aggregation of mutant uromodulin could affect wild-type protein function by interfering with 
its polymerisation or by sequestering it in large extracellular aggregates. This could affect the 
very recently described role of uromodulin in the regulation of water/salt balance in the TAL 
(24), contributing to urinary concentrating defect and hyperuricemia in UAKD phenotype. 
 
We believe that our findings have relevance when considering potential therapeutic strategies 
for UAKD, in particular the use of chemical chaperones to rescue mutant protein retention in 
the ER. The chemical chaperone sodium-phenylbutyrate (PBA) was shown to restore mutant 
uromodulin trafficking in vitro (25) and the use of this drug has already been extensively 
tested for the treatment of other ER-storage disorders such as alpha-1 antitrypsin deficiency 
(26) or cystic fibrosis (27). In the case of UAKD, chemical chaperones rescuing intracellular 
retention would likely increase mutant protein delivery to the plasma membrane thereby 
enhancing extracellular aggregation. We think that additional work would be needed to 
understand the potential negative consequences of such an effect that would be predicted to 
affect the TAL segment and kidney function. 
 
In conclusion, our work shows that mutant uromodulin isoforms are secreted in the urine of 
patients with preserved renal function. Mutant uromodulin seems to have a higher propensity 
to aggregation than the wild-type protein due to either misfolding or to different post-
translational modification, e.g. glycosylation. The formation of extracellular casts could 
induce tubule obstruction, cast formation and interfere with the function of wild-type 
uromodulin and possibly other membrane proteins. Thus, these data suggest that the 
proteotoxic effect of mutant uromodulin isoforms could be exerted through both intra-and 
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extracellular gain of function mechanisms. This should be taken into account when 
envisaging therapeutic strategies for uromodulin-associated renal disorders. 
 
METHODS 
 
Uromodulin expression constructs 
Wild-type uromodulin tagged with HA (pcDNA_HA_UMOD) was expressed from pcDNA 
3.1(+) cloning vector (Invitrogen, Carlsbad, CA). Missense mutations were introduced in 
pcDNA_HA_UMOD by using the Quickchange mutagenesis kit (Stratagene, La Jolla, CA) 
following the manufacturer’s instructions. Primers were designed using the software 
QuikChange® Primer Design Program. For co-expression experiments, myc- or Flag-tagged 
and HA-tagged uromodulin isoforms were stably expressed from bicistronic vector pVITRO-
hygro-mcs under the control of the elongation factor 1 alpha promoter of mouse and rat 
respectively (Invivogen, San Diego, CA). The HA, myc or Flag tag was inserted after the 
leader peptide, in between T26 and S27 in the protein sequence as previously described (28). 
 
Cell line and culture condition 
MDCK cells were grown in DMEM supplemented with 10% fetal bovine serum, 200 U/ml 
penicillin, 200 µg/ml streptomycin, and 2 mM glutamine (complete medium) at 37°C, 5% 
CO2. Stable clones were generated by transfecting MDCK cells with Lipofectamine 2000 
(Invitrogen) following the manufacturer’s protocol. For pcDNA and pVITRO constructs, 
selection was started 24 h after transfection by adding 1 mg/ml G418 (Invitrogen) or 200 
µg/ml hygromycin (Invitrogen) respectively, and was pursued for 2 weeks to obtain a 
population of resistant cells. 
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TgUmod mice and murine urine collection 
Generation and characterisation of TgUmod mice is described elsewhere (13). Murine urine was 
obtained on age- and gender-matched transgenic and control mice (females, aged 10-12 
weeks). They were housed in light- and temperature-controlled room with ad libitum access to 
water and standard chow. Twenty-four hours urine collections were obtained at baseline in 
individual metabolic cages. All animal procedures were carried out at San Raffaele Scientific 
Institute, Milan, Italy, according to and approved by the San Raffaele Institutional Animal 
Care and Use Committee.  
 
Patient and urine collection 
Diagnostic criteria for patient collection and UMOD mutational screening procedures have 
been previously described (6). Uromodulin was purified from 20 ml of urine as already 
reported (3), and resuspended in distilled water. Purified protein was deglycosylated with 
peptide-N-glycosidase F (PNGase F) (New England Biolabs, Ipswich, MA) in 
denaturing/reducing conditions according to the manufacturer’s instructions, alkylated in 55 
mM iodoacetamide (IAA) or N-ethylmaleimide (NEM) for 20 min at room temperature, 
separated on 8% acrylamide SDS–PAGE and stained with Coomassie Brilliant Blue (Sigma–
Aldrich Corporation, St Louis, MO). 
 
Western-blot 
MDCK cells were grown to confluence. The complete medium was replaced with 2 ml of 
Opti-MEM (Invitrogen). After 24 h, the conditioned medium was collected, 4 volumes of 
acetone were added, and precipitated proteins were resuspended in 100 µl of phosphate-
buffered saline (PBS). When indicated, cells were incubated with Pi-PLC digestion medium 
(DMEM; 20mM Tris-HCl pH 7.4; Pi-PLC 0.3U/ml (Invitrogen)) for 3 h in a 5% C02 
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atmosphere at 37°C. Cells were lysed in 300 µl of octylglucoside lysis buffer (50 mM Tris-
HCl, pH 7.4, 150 mM NaCl, 60 mM octylglucoside, and 1 mM phenylmethylsulfonyl 
fluoride) for 1 h at 4°C under rotation. Unsoluble fractions were resuspended in 50 µl of 
Laemmli buffer while soluble fractions were quantified by the Bio-Rad Protein Assay (Bio-
Rad, Hercules, CA). When indicated, soluble fractions or Pi-PLC digestion medium were 
deglycosylated with peptide-N-glycosidase F (PNGase F) or endoglycosidase H (EndoH) 
(New England Biolabs). Thirty µg of each protein lysate, 10 µl (1/5) of each unsoluble 
fraction, and 20 µl (1/5) of medium-precipitated proteins were loaded onto reducing 8% SDS-
polyacrylamide gel electrophoresis (PAGE). Transblotted nitrocellulose membranes (GE 
Healthcare, Little Chalfont, Buckinghamshire, United Kingdom) were incubated with mouse 
monoclonal antibody (mAb) against HA (1:2000 dilution; Covance Reseach Products, 
Princeton, NJ) or myc (1:1000 dilution; Covance) followed by incubation with horseradish 
peroxidase-conjugated secondary antibody (1:7500 dilution; GE Healthcare). Anti alpha-
tubulin mouse mAb (1:1000 dilution; Santa Cruz Biotechnology, Santa Cruz, CA) and 
polyclonal anti-transferrin goat antibody (1:1000 dilution; Bethyl laboratories, inc, 
Montgomery, TX) were used as a loading control for lysate and precipitated medium 
respectively. Protein bands were visualized with the Immobilon Western Chemiluminescent 
Horseradish Peroxidase Substrate kit (Millipore, Billerica, MA). 
 
Sucrose gradient 
Pi-PLC digestion medium was overlaid on a discontinuous gradient consisting of 1, 1.5 and 2 
M sucrose in DMEM and centrifuged at 100 000 g for 2 h. After centrifugation, the gradient 
was separated in 6 fractions that were precipitated with acetone and analysed by western-blot 
using a sheep anti-uromodulin antibody (1:1000 dilution, Abcam, Cambridge, UK). 
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Immunoprecipitation 
MDCK cells grown to confluence (3 100 mm dishes/line) were kept for 30 h in Opti-MEM 
(Invitrogen). The conditioned medium was collected, pooled and concentrated on Amicon-
Ultra-15 3K (Millipore) to obtain a total volume of 700 µl. 500 µl of the concentrated medium 
was added to 40 µl of anti-Flag M2 affinity gel (Sigma). After an overnight incubation at 4°C 
under rotation, the resin was washed 3 times with 1 mL PBS, resuspended in 60 µl Laemmli 
buffer and boiled. 50 µl of the concentrated medium and 30 µl of the immunoprecipitate were 
loaded on SDS PAGE and analysed by western-blot as described above using a rabbit anti-
Flag antibody (1:2000 dilution, Sigma) or a mouse anti-HA antibody (1:1000 dilution, 
Covance). 
 
Immunofluorescence 
Cells grown on coverslip in 12-wells plate were fixed in 4% paraformaldehyde (PFA) for 30 
min. When needed, cells were permeabilised 10 min at room temperature with 0.5% Triton X-
100. Cells were labelled for 1 h 30 min at room temperature with anti-HA (1:500; Covance) 
and anti-myc (1:500; Novus Biologicals, Littleton, CO) and anti-calnexin (dilution 1:500; 
Sigma-Aldrich) antibodies. After incubation with the appropriate secondary antibody (1:500; 
Invitrogen) cells were stained with 4,6-diamidino-2-phenylindole (DAPI) and mounted using 
FluorSave Reagent (Calbiochem, San Diego, CA).  
To collect renal tissue, animals were anaesthetised with avertin and perfused with a 4% PFA 
solution. Kidneys were taken and fixed in 4% PFA solution for additional 16 h and embedded 
in optimum cutting temperature embedding medium (Tissue-Tek, Electron Microscopy 
Sciences, Hatfield, PA), snap-frozen in a mixture of isopentane and dry ice, and stored at –
80°C. Immunofluorescence was carried out on tissue sections (10 µm thick) stained with rat 
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anti-HA antibody (Roche, Indianapolis, IN) and anti-NKCC2 antibody (kind gift from Prof. 
Sebastian Bachmann, Charité University, Berlin). 
All slides were visualized under a DM 5000B fluorescence upright microscope (Leica 
DFC480 camera, Leica DFC Twain Software, 40X/0.75 lens; Leica Microsystems, Deerfield, 
IL) or with an UltraVIEW ERS spinning disk confocal microscope (UltraVIEW ERS-Imaging 
Suite Software, Zeiss 63X/1.4; PerkinElmer Life and Analytical Sciences Boston, MA). All 
images were imported in Photoshop CS (Adobe Systems, Mountain View, CA) and adjusted 
for brightness and contrast.  
The area of polymers covering the plasma membrane in cells co-expressing myc-tagged wild-
type uromodulin together with either wild-type or mutant HA-tagged protein was quantified 
by using Image J software (http://imagej.nih.gov/ij/) (Figure S7). The analysis was performed 
on pictures taken at 10X magnification that were adjusted for brightness and contrast and after 
setting a threshold to exclude the membrane signal background. Only polymers positive for 
both tags were quantified by setting a selection mask on the HA channel and restoring it on 
the myc one. The selected area was quantified by setting an object size limit of 300 pixels. 
For each experiment, about 1000 objects were quantified per line. Data are expressed as 
average ± SEM and compared by unpaired two-tailed t test analysis (Prism software; 
GraphPad, San Diego, CA). 
 
Mass-spectrometry analysis 
LC-MS/MS analysis 
Bands of interest were excised from gels of patients, subjected to reduction by 10 mM 
dithiothreitol (DTT) and alkylation by 55 mM IAA or NEM, and finally digested overnight 
with trypsin (Roche) (29). After acidification, up to 10% formic acid, peptide mixtures were 
concentrated and desalted on StageTips µC18 (Proxeon Biosystem, Odense, Denmark) (30) 
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and injected in a capillary chromatographic system (EasyLC, Proxeon Biosystem, Odense, 
Denmark). Peptide separations occurred on a RP homemade 15 cm reverse-phase spraying 
fused silica capillary column (75 µm i.d. x 15 cm), packed with 3 µm ReproSil-Pur C18-AQ 
(Dr. Maisch GmbH, Germany). A gradient of eluents A (H2O with 2% v/v ACN, 0.5% v/v 
acetic acid) and B (80%ACN with 0.5% v/v acetic acid) was used to achieve separation, from 
7% B (at 0 min 0.2 µL/min flow rate) to 35% B (in 70 min, 0.2 µL/min flow rate). The LC 
system was connected to an LTQ-Orbitrap mass spectrometer (Thermo Fisher Scientific, 
Waltham, MA) equipped with a nanoelectrospray ion source (Proxeon Biosystems). MS and 
MS/MS spectra were acquired selecting the ten most intense ions per survey spectrum 
acquired in the orbitrap from m/z 300-1750 with 60 000 resolution. Target ions selected for 
the MS/MS were fragmented in the ion trap and dynamically excluded for 45s. Target value 
were 1 000 000 for survey scan and 100 000 for MS/MS scan. For accurate mass 
measurements, the lock-mass option was employed (31). 
Data Processing and Analysis 
For peptide identifications Mascot (Matrix Science; version 2.2.07) search engine was used. 
Raw MS files were converted into peaklist (.msm files), and searched against the database 
IPI_human_20100628 (86 397 sequences; 35 097 130 residues) supplemented with the on 
purpose created sequences of human uromodulin variants with mutations R212C 
(IPI99999999), C256Y (IPI99999996) and C317Y (IPI99999995). 
Enzyme specificity was set to trypsin, allowing a maximum of two missed cleavages. 
Cysteine alkylation by IAA or NEM or acrylamide, oxidation of methionine, deamidation of 
asparagine and protein N-acetylation were all considered as variable modifications. Mass 
tolerance was set to 5 ppm and 0.6 Da for precursor and fragment ions respectively. The 
criteria used to evaluate the quality of MS/MS data was a Mascot ion score cut-off of at least 
20. 
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Data Analysis by MaxQuant 
To measure the intensity of peptides, especially the intensity of the mutated peptides and the 
correspondent wild-type peptides in each sample from urine of patients, MS data were 
analyzed using the MaxQuant software, (32, 33) version 1.1.1.25 applying the Label-free 
algorithms. 
For MS/MS peak list file construction, up to top 6 peaks per 100 Da window were included 
for database searching. The generated peak lists were searched against the concatenated 
forward and reverse database IPI_human_20100628 (86 397 sequences; 35 097 130 residues) 
supplemented with the on purpose created sequences of human uromodulin variants with 
mutations R212C (IPI99999999), C256Y (IPI99999996) and C317Y (IPI99999995). Mass 
tolerance was set to 7 ppm and 0.6 Th for precursor and fragment ions respectively. Cysteine 
alkylation by IAA or NEM and acrylamide, protein N-terminal acetylation, asparagine 
deamidation and methionine oxidation were set as variable modifications for the database 
search. The cut-off false discovery rate for proteins and peptides was set to 0.01, and peptides 
with a minimum of six amino acids were considered for identification. The derived peptides 
intensities were used for a rough estimation of relative peptide abundances. 
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FIGURE LEGENDS 
 
Figure 1. (a) Schematic representation of uromodulin. The three EGF domains are 
represented by orange boxes, the D8C domain by a pink box and the ZP domain (composed 
of ZP_N and ZP_C subdomains) is represented in blue. The GPI anchoring site as well as the 
glycosylation sites (Y) are shown. Studied mutations are indicated in red. (b) Pedigree charts 
of the three families D123, MCKD1 and CM1 bearing uromodulin mutations R212C, C256Y 
and C317Y respectively. *, urine mass-spectrometry analysis. 
 
Figure 2. (a) Immunofluorescence analysis showing uromodulin in permeabilised MDCK 
cells stably expressing HA-tagged wild-type or mutant uromodulin isoforms. Calnexin is 
shown as an ER marker. Bar = 35 µm (b) Western-blot detection of HA-tagged wild-type 
uromodulin or indicated mutants from the medium (M) and the soluble (L) and unsoluble (P) 
fractions of protein extracts from stably transfected MDCK cells. Tubulin is shown as a 
loading control (left panel). Western-blot detection of uromodulin present in the cell lysate 
after deglycosylation with Endo H (E) or PNGase F (P); C, untreated sample (right panel). 
 
Figure 3. Immunofluorescence showing uromodulin distribution on the plasma membrane in 
unpermeabilised MDCK cells stably expressing HA-tagged wild-type or mutant uromodulin 
isoforms. Wild-type isoform is mainly present as large polymeric filaments while mutant 
isoforms form extracellular bulky aggregates. Bar = 35 µm. 
 
Figure 4. (a) Immunofluorescence analysis showing uromodulin on the plasma membrane of 
unpermeabilised MDCK cells stably expressing myc-tagged wild-type isoform and either 
wild-type or mutant HA-tagged isoforms. Staining with anti-HA and anti-myc antibodies are 
 27 
shown. The presence of the mutant isoform at the plasma membrane interferes with the 
polymerisation of the wild-type one, as polymers look shortened and more aggregated. Bar = 
55 µm. (b) Quantification of the average surface of uromodulin polymers on the membrane of 
MDCK cells co-expressing HA- and myc-tagged uromodulin isoforms. Only polymers 
containing co-transfected isoforms (positive for both tags) were quantified (about 1000 counts 
per cell line per experiment, 2 independent experiments). Filaments formed by wild-type and 
mutant protein are significantly shortened. **, p < 0.001. 
 
Figure 5. Western-blot analysis after separation on sucrose gradient of uromodulin digested 
by Pi-PLC from MDCK cells expressing the myc-tagged wild-type isoform and either wild-
type or mutant HA-tagged isoforms. Fractions numbers are indicated from the top (1M 
sucrose, fraction 1) to the bottom (2M sucrose, fraction 6) of the gradient. I, input (1/5 of the 
amount loaded on the gradient). Uromodulin sediments deeper in the gradient when wild type 
protein is expressed alone. 
 
Figure 6. Top panel: Co-immunoprecipitation experiments on protein from the conditioned 
medium of MDCK cells co-expressing Flag-tagged wild-type and HA-tagged uromodulin 
isoforms. Immunoprecipitation was carried out with an anti-Flag antibody. The presence of 
co-immunoprecipitated HA-tagged uromodulin was assessed by western-blot analysis. Mutant 
uromodulin co-assembles with wild-type protein. Bottom panel: Same experiment performed 
on protein from the conditioned medium of MDCK cells expressing HA-tagged wild-type 
uromodulin isoform. The absence of co-immunoprecipitated HA-tagged uromodulin in the 
absence of Flag-tagged isoform demonstrates the specificity of the assay. *, unspecific signal, 
IP: immunoprecipitate. 
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Figure 7. (a) Transgenic HA-tagged uromodulin secreted in urine of TgUmodwt and 
TgUmodC147W mice was analysed by western-blot. C, control non-transgenic animal. The 
amount of urine loaded is representative of a 24 h urine collection. Urinary uromodulin was 
also analysed after deglycosylation with PNGase F. (b) Immunofluorescence performed on 
kidney sections of TgUmodwt and TgUmodC147W mice showing transgenic uromodulin and 
NKCC2 (apical marker of TAL epithelial cells). Uromodulin aggregates are present 
exclusively in TAL lumen of TgUmodC147W mice. Bar = 50µm (c) Immunofluorescence 
showing at higher magnification uromodulin aggregates present in TAL lumen of TgUmodC147W 
mice and absent in TgUmodwt mice. Bar = 50µm. 
 29 
Table 1. Summary of clinical features in the UAKD patients analysed. 
Uromodulin 
mutation 
Patient Sex Age at urine 
collection 
Urine specific 
gravity 
Urinary 
creatinine 
(mg/dl) 
Serum 
creatinine 
(mg/dl) 
Serum 
uric acid 
(mg/dl) 
Gout Renal 
ultrasound 
R212C II 1 M 41 1010 65,5 1,08 6,2 No NK 
C256Y II 4 M 35 1018 73 1,4 8,9 No NK 
C317Y IV 5 M 18 1020 80 0,8 7,5 No NK 
NK, normal kidneys. 
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Table 2. Intensities of specific peptides belonging to wild-type and mutant uromodulin isoforms as detected in urine samples from UAKD 
patients and calculation of their relative abundance. 
Sequence Mass Accession Number PEP Intensity sample 
wt/mutant 
peptide intensity 
%mutant vs 
wt 
Patient II-1 (R212C)       
FVGQGGACMAETCVPVLR 1836 IPI99999999 2,843E-3 703400 76,3 1,3% 
FVGQGGAR 790 IPI00013945 9,630E-3 231460   
MAETCVPVLR 1117 IPI00013945 5,089 E-3 53459000   
Patient II-4 (C256Y)       
ACAHWSGHCCLWDASVQVK 2099 IPI00013945 7,90E-11 293380000 13,12 7,6% 
ACAHWSGHCYLWDASVQVK 2159 IPI99999996 3,85E-08 29253000   
KACAHWSGHCCLWDASVQVK 2228 IPI00013945 1,03E-14 90289000   
Patient IV-5 (C317Y)       
WHCQCK 803 IPI00013945 0,39716 2342100 2,80 35,7% 
WHCQCKQDFNITDISLLEHR 2485 IPI00013945 6,92E-08 3591500   
WHCQYKQDFNITDISLLEHR 2545 IPI99999995 0,036102 2434900   
SNNGRWHCQCK 1331 IPI00013945 0,011313 281370   
SNNGRWHCQCKQDFNITDISLLEHR 3013 IPI00013945 0,025424 598510   
Mass: mass of the fragmented peptide. PEP: Posterior Error Probability (probability of a false hit given the peptide identification score and length of peptides. The mutated 
amino acid is highlighted in bold. 
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SUPPLEMENTARY FIGURE LEGENDS 
 
Supplementary Figure 1. Western-blot analysis of HA-tagged uromodulin released after 
PLC cleavage from MDCK cell plasma membrane and deglycosylated with PNGase F or 
EndoH; control, untreated sample. 
 
Supplementary Figure 2. Western-blot analysis of uromodulin from MDCK cells expressing 
myc-tagged wild-type and either wild-type or mutant HA-tagged isoforms. Both uromodulin 
present in the cell lysate (top row) and secreted in the medium (bottom row) are shown. 
Tubulin and transferrin are shown as loading controls. 
 
Supplementary Figure 3. MS/MS spectra of the wild-type peptide (a) and the correspondent 
mutated peptide (b) obtained by analysis of uromodulin purified from the urine of patient with 
R212C mutation. 
 
Supplementary Figure 4. MS/MS spectra of the wild-type peptide (a) and the correspondent 
mutated peptide (b) obtained by analysis of uromodulin purified from the urine of patient with 
C256Y mutation. 
 
Supplementary Figure 5. MS/MS spectra of the wild-type peptide (a) and the correspondent 
mutated peptide (b) obtained by analysis of uromodulin purified from the urine of patient with 
C317Y mutation. 
 
Supplementary Figure 6. Immunofluorescence performed on kidney sections of TgUmodwt 
and TgUmodC147W mice at 1 week of age showing transgenic HA-tagged uromodulin. 
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Uromodulin aggregates are present exclusively in TAL lumen of TgUmodC147W mice. Bar = 25 
µm. 
 
Supplementary Figure 7. Representative pictures for the quantification of polymer average 
area on unpermeabilised MDCK cells expressing myc-tagged wild-type and either wild-type 
or mutant (C317Y) HA-tagged uromodulin isoforms. Top row: merged myc (green) and HA 
(red) signal. Bottom row: selection outline defining quantified areas. Bar = 100 µm. 
 
 
